{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T11:15:16Z","timestamp":1791544516134,"version":"4.3.4"},"reference-count":61,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"vor","delay-in-days":26,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100031004","name":"KalVista Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031004","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical &amp; Translational All"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Hereditary angioedema (HAE) is a rare genetic disorder characterized by unpredictable, debilitating episodes of submucosal and\/or subcutaneous tissue swelling, which may be life\u2010threatening depending on anatomic location. The two primary management strategies for HAE are ready access to effective on\u2010demand treatment in all patients and the prevention of attacks (short\u2010term prophylaxis [STP] and long\u2010term prophylaxis [LTP]) in appropriate patients. All approved on\u2010demand and most LTP medications require subcutaneous or intravenous administration. Injection\u2010related challenges include trypanophobia (fear of needles), difficulty with self\u2010administration, injection\u2010site reactions (e.g., pain, erythema, bleeding, bruising), and anxiety\u2014all contributing to poor compliance and administration delays. Oral HAE treatments may improve outcomes by reducing treatment barriers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To review oral therapies, approved or in development, for on\u2010demand treatment and\/or prevention of HAE attacks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>To provide a comprehensive review, data was obtained from publicly available resources through a targeted PubMed literature review and supplemented by information provided on company websites (search cutoff of May 31, 2024).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Berotralstat, an oral plasma kallikrein (PKa) inhibitor, is approved for LTP. Sebetralstat, another PKa inhibitor, is the investigational first oral on\u2010demand HAE treatment to complete a phase 3 trial. Deucrictibant, an oral bradykinin B2 receptor antagonist, has completed phase 2 trials for on\u2010demand therapy and LTP. Several other oral PKa inhibitors (ATN249, VE\u20104666, and VE\u20104062) are in early development for LTP.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Substantial advances have been made in the development of oral treatments for HAE. These treatments have the potential to improve and optimize clinical outcomes, satisfaction, and quality of life among patients with HAE.<\/jats:p><\/jats:sec>","DOI":"10.1002\/clt2.12391","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T17:29:02Z","timestamp":1727458142000},"source":"Crossref","is-referenced-by-count":15,"title":["Advent of oral medications for the treatment of hereditary angioedema"],"prefix":"10.1002","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0417-9840","authenticated-orcid":false,"given":"Anna","family":"Valerieva","sequence":"first","affiliation":[{"name":"Department of Allergology Medical University of Sofia University Hospital \u201cAlexandrovska\u201d  Sofia Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Caballero","sequence":"additional","affiliation":[{"name":"Servicio de Alergia Hospital Universitario la Paz IdiPAZ CIBERER U754  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Magerl","sequence":"additional","affiliation":[{"name":"Institute of Allergology IFA Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin  Berlin Germany"},{"name":"Fraunhofer Institute for Translational Medicine and Pharmacology ITMP Allergology and Immunology  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joao P.","family":"Frade","sequence":"additional","affiliation":[{"name":"KalVista Pharmaceuticals  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul K.","family":"Audhya","sequence":"additional","affiliation":[{"name":"KalVista Pharmaceuticals  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7774-4855","authenticated-orcid":false,"given":"Timothy","family":"Craig","sequence":"additional","affiliation":[{"name":"Departments of Medicine, Pediatrics, and Biomedical Sciences Penn State University  Hershey Pennsylvania USA"},{"name":"Vinmec Medical Center  Times City Hanoi Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,9,27]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2021.11.011"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.7573\/dic.212605"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13223\u2010021\u201000537\u20102"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.15214"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.12.441"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2023.03.1812"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2021.42.210025"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2024.45.230073"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2020.08.046"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2314192"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.12.419"},{"key":"e_1_2_8_13_1","volume-title":"Danazol","year":"2000"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/0091\u20106749(77)90080\u2010x"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejm197208312870907"},{"key":"e_1_2_8_16_1","volume-title":"Orladeyo","year":"2022"},{"key":"e_1_2_8_17_1","volume-title":"Orladeyo","year":"2021"},{"issue":"10","key":"e_1_2_8_18_1","article-title":"Assessing the potential benefits of oral therapies in hereditary angioedema [AMCP abstract D11]","volume":"29","author":"Soteres D","year":"2023","journal-title":"J Manag Care Spec Pharm"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1080\/21556660.2020.1863699"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2018.39.4095"},{"key":"e_1_2_8_21_1","unstructured":"BuksteinD DesaiV GogaL BrownM SettipaneR.Preferences of people with hereditary angioedema for on\u2010demand treatment: a US\u2010based qualitative study. Accessed January 16 2024.https:\/\/easternallergyconference.org\/past\u2010meeting\u2010abstracts"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.3389\/falgy.2022.952233"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.2c00921"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(22)02406\u20100"},{"key":"e_1_2_8_25_1","unstructured":"KalVista Pharmaceuticals Ltd.An open\u2010label extension trial to evaluate the long\u2010term safety of KVD900 for on\u2010demand treatment of angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE). ClinicalTrials.gov identifier: NCT05505916.2023."},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.12.438"},{"key":"e_1_2_8_27_1","unstructured":"MaurerM.Dose\u2010ranging study of oral PHA\u2010022121 for acute treatment of angioedema attacks in patients with hereditary angioedema (RAPIDe\u20101). ClinicalTrials.gov identifier: NCT04618211.2023."},{"key":"e_1_2_8_28_1","unstructured":"FarkasH AndersonJ Ayg\u00f6ren\u2010P\u00fcrs\u00fcnE et\u00a0al.Efficacy and safety of the oral bradykinin B2 receptor antagonist PHVS416 in treatment of hereditary angioedema attacks: topline results of RAPIDe\u20101 phase 2 trial [C1\u2010INH 2023 abstract O19]. Abstract presented at: 13th C1\u2010Inhibitor Deficiency & Angioedema Workshop; May 4\u20107 2023; Budapest Hungary. Accessed September 20 2023.https:\/\/haei.org\/c1\u2010inh\u20102023\/"},{"key":"e_1_2_8_29_1","unstructured":"Science.http:\/\/www.pharvaris.com\/science. Accessed October 13 2023."},{"key":"e_1_2_8_30_1","unstructured":"Pharvaris NetherlandsBV.Study of oral deucrictibant soft capsule for on\u2010demand treatment of angioedema attacks in adolescents and adults with hereditary angioedema (RAPIDe\u20103). ClinicalTrials.gov identifier: NCT06343779.2024."},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.12.112"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0278\u20102391(99)90280\u2010x"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.12032"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13223-019-0376-8"},{"key":"e_1_2_8_35_1","unstructured":"IversonM DuckworthE HansenE et\u00a0al.Rationale for the short\u2010term prophylaxis regimen with sebetralstat in KONFIDENT\u2010S [C1\u2010INH 2023 abstract O16]. Abstract presented at: 13th C1\u2010Inhibitor Deficiency & Angioedema Workshop; May 4\u20107 2023; Budapest Hungary. Accessed September 20 2023.https:\/\/haei.org\/c1\u2010inh\u20102023\/"},{"key":"e_1_2_8_36_1","volume-title":"Orladeyo","year":"2021"},{"key":"e_1_2_8_37_1","unstructured":"BioCryst received UK approval of Orladeyo\u2122 (berotralstat) first oral once\u2010daily therapy to prevent attacks in hereditary angioedema patients.;2022.https:\/\/ir.biocryst.com\/news\u2010releases\/news\u2010release\u2010details\/biocryst\u2010receives\u2010uk\u2010approval\u2010orladeyotm\u2010berotralstat\u2010first\u2010oral. Accessed October 9 2023."},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.10.015"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2021.03.057"},{"key":"e_1_2_8_40_1","article-title":"Once\u2010daily oral berotralstat for long\u2010term prophylaxis of hereditary angioedema: the open\u2010label extension of the APeX\u20102 randomized trial","author":"Kiani\u2010Alikhan S","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.14670"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/clt2.12035"},{"key":"e_1_2_8_43_1","unstructured":"FarkasH.A long term safety study of BCX7353 in hereditary angioedema (APeX\u2010S). ClinicalTrials.gov identifier: NCT03472040.2023."},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2021.08.083"},{"key":"e_1_2_8_45_1","unstructured":"BucklandM.Berotralstat treatment in children with hereditary angioedema (APeX\u2010P). ClinicalTrials.gov identifier: NCT05453968.2023."},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/0091\u20106749(80)90181\u20105"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003\u20104819\u201093\u20106\u2010809"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejm197612232952602"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2004.12.1130"},{"key":"e_1_2_8_50_1","unstructured":"RiedlM Ayg\u00f6ren\u2010P\u00fcrs\u00fcnE.Dose\u2010ranging study of oral PHA\u2010022121 for prophylaxis against angioedema attacks in patients with hereditary angioedema type I or type II (HAE CHAPTER\u20101). ClinicalTrials.gov identifier: NCT05047185.2023."},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2023.11.057"},{"key":"e_1_2_8_52_1","unstructured":"Pharvaris announces positive top\u2010line phase 2 data from the CHAPTER\u20101 study of deucrictibant for the prophylactic treatment of HAE attacks.2023.https:\/\/ir.pharvaris.com\/news\u2010releases\/news\u2010release\u2010details\/pharvaris\u2010announces\u2010positive\u2010top\u2010line\u2010phase\u20102\u2010data\u2010chapter\u20101. Accessed February 7 2024."},{"key":"e_1_2_8_53_1","unstructured":"CHAPTER\u20101 trial of HAE therapy deucrictibant completes enrollment;2023.https:\/\/angioedemanews.com\/news\/chapter\u20101\u2010trial\u2010hae\u2010therapy\u2010deucrictibant\u2010completes\u2010enrollment\/. Accessed September 19 2023."},{"key":"e_1_2_8_54_1","unstructured":"Pipeline.http:\/\/www.pharvaris.com\/pipeline. Accessed September 19 2023."},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2022.08.596"},{"issue":"4","key":"e_1_2_8_56_1","article-title":"Pharmacokinetics, safety, and potency of ATN\u2010249, a novel oral plasma kallikrein inhibitor for hereditary angioedema","volume":"15","author":"Kalfus I","year":"2019","journal-title":"Allergy Asthma Clin Immunol"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.03.038"},{"key":"e_1_2_8_58_1","unstructured":"Programs.http:\/\/www.attunepharma.com\/programs. Accessed September 13 2023."},{"key":"e_1_2_8_59_1","unstructured":"Attune pharmaceuticals announces positive phase 1 results for ATN\u2010249 an oral plasma kallikrein inhibitor for the treatment of HAE.2019.http:\/\/attunepharma.com\/assets\/Attune\u2010Phase\u20101_2019_01_22.pdf. Accessed September 19 2023."},{"key":"e_1_2_8_60_1","unstructured":"Pipeline.http:\/\/www.verseon.com\/pipeline.html. Accessed September 20 2023."},{"key":"e_1_2_8_61_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.13466"},{"key":"e_1_2_8_62_1","unstructured":"KalVista Pharmaceuticals.A trial to evaluate the efficacy and safety of different doses of KVD824 for prophylactic treatment of HAE type I or II (KVD824\u2010201). ClinicalTrials.gov identifier: NCT05055258.2023."}],"container-title":["Clinical and Translational Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/clt2.12391","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T00:44:38Z","timestamp":1727484278000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/clt2.12391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":61,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["10.1002\/clt2.12391"],"URL":"https:\/\/doi.org\/10.1002\/clt2.12391","archive":["Portico"],"relation":{},"ISSN":["2045-7022","2045-7022"],"issn-type":[{"value":"2045-7022","type":"print"},{"value":"2045-7022","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9]]},"article-number":"e12391"}}